Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report

Area of Science:

• Oncology
• Molecular Biology
• Gastroenterology

Background:

• Advanced gastric adenocarcinoma is a challenging diagnosis with limited treatment options.
• KIT mutations are implicated in the pathogenesis of some gastric cancers.
• Targeted therapies offer a promising avenue for improving patient outcomes.

Observation:

• This study investigated the potential of imatinib, a tyrosine kinase inhibitor, in treating advanced gastric adenocarcinoma.
• The presence of KIT mutations was a key factor in patient selection.
• Clinical responses and safety profiles were assessed.

Findings:

• Imatinib demonstrated therapeutic potential in a subset of patients with advanced gastric adenocarcinoma.
• Patients harboring KIT mutations exhibited a notable response to imatinib treatment.
• The targeted approach warrants further investigation.

Implications:

• Imatinib could represent a valuable targeted therapy for a specific patient population with advanced gastric adenocarcinoma.
• Identifying KIT mutations is crucial for selecting appropriate candidates for imatinib therapy.
• This finding may inform future treatment strategies and clinical trial designs for gastric cancer.